RESUMO
Over the past few decades,biomarkers have become increasingly utilized as non-invasive tools in the early diagnosis and management of various clinical conditions.In perinatal medicine,the improved survival of infants who are at high risk for adverse neurologic outcomes has increased the demand for the discovery of biomarkers in detecting and predicting the prognosis of in term and preterm newborns with neonatal brain injury.Recognization potential brain damage early is crucial because clinical feature and monitoring parameters may be of no avail and therapeutic window for pharmacological intervention is very limited.Therefore,the measurement of biochemical markers of brain damage is eagerly awaited in clinical practice to detect high risk infants.These biomarkers could allow clinicians to intervene at the early stages of disease,and to monitor the efficacy of those interventions.None,however,were studied extensively enough to warrant routine clinical use.The present paper is aimed at investigating the role of the main biomarkers such as activing A,S100B,glial fibrillary acidic protein,adrenomedullin,neuron-specific enolase,interleukin-6,hemeoxygenase-1,transforming growth factor β,uric acid,nucleated red blood cells,currently studied in infants with neonatal brain injury.